1607 related articles for article (PubMed ID: 16873678)
1. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice.
Dentin R; Benhamed F; Hainault I; Fauveau V; Foufelle F; Dyck JR; Girard J; Postic C
Diabetes; 2006 Aug; 55(8):2159-70. PubMed ID: 16873678
[TBL] [Abstract][Full Text] [Related]
2. Deficiency of carbohydrate-activated transcription factor ChREBP prevents obesity and improves plasma glucose control in leptin-deficient (ob/ob) mice.
Iizuka K; Miller B; Uyeda K
Am J Physiol Endocrinol Metab; 2006 Aug; 291(2):E358-64. PubMed ID: 16705063
[TBL] [Abstract][Full Text] [Related]
3. Role of ChREBP in hepatic steatosis and insulin resistance.
Denechaud PD; Dentin R; Girard J; Postic C
FEBS Lett; 2008 Jan; 582(1):68-73. PubMed ID: 17716660
[TBL] [Abstract][Full Text] [Related]
4. Altered expression of transcription factors and genes regulating lipogenesis in liver and adipose tissue of mice with high fat diet-induced obesity and nonalcoholic fatty liver disease.
Morgan K; Uyuni A; Nandgiri G; Mao L; Castaneda L; Kathirvel E; French SW; Morgan TR
Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):843-54. PubMed ID: 18794597
[TBL] [Abstract][Full Text] [Related]
5. Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes.
Matsusue K; Haluzik M; Lambert G; Yim SH; Gavrilova O; Ward JM; Brewer B; Reitman ML; Gonzalez FJ
J Clin Invest; 2003 Mar; 111(5):737-47. PubMed ID: 12618528
[TBL] [Abstract][Full Text] [Related]
6. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression.
Sekiya M; Yahagi N; Matsuzaka T; Najima Y; Nakakuki M; Nagai R; Ishibashi S; Osuga J; Yamada N; Shimano H
Hepatology; 2003 Dec; 38(6):1529-39. PubMed ID: 14647064
[TBL] [Abstract][Full Text] [Related]
7. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
8. A novel aminosterol reverses diabetes and fatty liver disease in obese mice.
Takahashi N; Qi Y; Patel HR; Ahima RS
J Hepatol; 2004 Sep; 41(3):391-8. PubMed ID: 15336441
[TBL] [Abstract][Full Text] [Related]
9. Dietary capsaicin reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet.
Kang JH; Goto T; Han IS; Kawada T; Kim YM; Yu R
Obesity (Silver Spring); 2010 Apr; 18(4):780-7. PubMed ID: 19798065
[TBL] [Abstract][Full Text] [Related]
10. Abrogation of hepatic ATP-citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor-deficient mice.
Wang Q; Jiang L; Wang J; Li S; Yu Y; You J; Zeng R; Gao X; Rui L; Li W; Liu Y
Hepatology; 2009 Apr; 49(4):1166-75. PubMed ID: 19177596
[TBL] [Abstract][Full Text] [Related]
11. Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c.
Ferré P; Foufelle F
Diabetes Obes Metab; 2010 Oct; 12 Suppl 2():83-92. PubMed ID: 21029304
[TBL] [Abstract][Full Text] [Related]
12. ChREBP, a transcriptional regulator of glucose and lipid metabolism.
Postic C; Dentin R; Denechaud PD; Girard J
Annu Rev Nutr; 2007; 27():179-92. PubMed ID: 17428181
[TBL] [Abstract][Full Text] [Related]
13. Partial leptin deficiency favors diet-induced obesity and related metabolic disorders in mice.
Begriche K; Lettéron P; Abbey-Toby A; Vadrot N; Robin MA; Bado A; Pessayre D; Fromenty B
Am J Physiol Endocrinol Metab; 2008 May; 294(5):E939-51. PubMed ID: 18349116
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment with novel glycogen synthase kinase-3 inhibitor improves glucose homeostasis in ob/ob mice: molecular characterization in liver and muscle.
Kaidanovich-Beilin O; Eldar-Finkelman H
J Pharmacol Exp Ther; 2006 Jan; 316(1):17-24. PubMed ID: 16169938
[TBL] [Abstract][Full Text] [Related]
15. Beta-aminoisobutyric acid prevents diet-induced obesity in mice with partial leptin deficiency.
Begriche K; Massart J; Abbey-Toby A; Igoudjil A; Lettéron P; Fromenty B
Obesity (Silver Spring); 2008 Sep; 16(9):2053-67. PubMed ID: 19186330
[TBL] [Abstract][Full Text] [Related]
16. Insulin resistance and steatosis in humans.
Capeau J
Diabetes Metab; 2008 Dec; 34(6 Pt 2):649-57. PubMed ID: 19195626
[TBL] [Abstract][Full Text] [Related]
17. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice.
Yu XX; Murray SF; Pandey SK; Booten SL; Bao D; Song XZ; Kelly S; Chen S; McKay R; Monia BP; Bhanot S
Hepatology; 2005 Aug; 42(2):362-71. PubMed ID: 16001399
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis.
Lee YS; Shin S; Shigihara T; Hahm E; Liu MJ; Han J; Yoon JW; Jun HS
Diabetes; 2007 Jun; 56(6):1671-9. PubMed ID: 17369525
[TBL] [Abstract][Full Text] [Related]
19. Leptin deficiency per se dictates body composition and insulin action in ob/ob mice.
van den Hoek AM; Teusink B; Voshol PJ; Havekes LM; Romijn JA; Pijl H
J Neuroendocrinol; 2008 Jan; 20(1):120-7. PubMed ID: 18081560
[TBL] [Abstract][Full Text] [Related]
20. Increased hepatic lipogenesis in insulin resistance and Type 2 diabetes is associated with AMPK signalling pathway up-regulation in Psammomys obesus.
Ben Djoudi Ouadda A; Levy E; Ziv E; Lalonde G; Sané AT; Delvin E; Elchebly M
Biosci Rep; 2009 Jun; 29(5):283-92. PubMed ID: 18842111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
